Rifaximin Improves Clostridium difficile Toxin A-Induced Toxicity in Caco-2 Cells by the PXR-Dependent TLR4/MyD88/NF-κB Pathway by Giuseppe Esposito et al.
fphar-07-00120 May 5, 2016 Time: 16:44 # 1
ORIGINAL RESEARCH
published: 09 May 2016
doi: 10.3389/fphar.2016.00120
Edited by:
Raffaele Capasso,
University of Naples Federico II, Italy
Reviewed by:
Laurent Ferrier,
Institut National de la Recherche
Agronomique, France
Ignazio Castagliuolo,
University of Padova, Italy
*Correspondence:
Giovanni Sarnelli
sarnelli@unina.it;
Giuseppe Esposito
giuseppe.esposito@uniroma1.it
Specialty section:
This article was submitted to
Gastrointestinal and Hepatic
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 01 March 2016
Accepted: 25 April 2016
Published: 09 May 2016
Citation:
Esposito G, Nobile N, Gigli S,
Seguella L, Pesce M, d’Alessandro A,
Bruzzese E, Capoccia E, Steardo L,
Cuomo R and Sarnelli G (2016)
Rifaximin Improves Clostridium difficile
Toxin A-Induced Toxicity in Caco-2
Cells by the PXR-Dependent
TLR4/MyD88/NF-κB Pathway.
Front. Pharmacol. 7:120.
doi: 10.3389/fphar.2016.00120
Rifaximin Improves Clostridium
difficile Toxin A-Induced Toxicity in
Caco-2 Cells by the PXR-Dependent
TLR4/MyD88/NF-κB Pathway
Giuseppe Esposito1*, Nicola Nobile1, Stefano Gigli1, Luisa Seguella1, Marcella Pesce2,
Alessandra d’Alessandro2, Eugenia Bruzzese3, Elena Capoccia1, Luca Steardo1,
Rosario Cuomo2 and Giovanni Sarnelli2*
1 Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, Rome, Italy, 2 Department
of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy, 3 Department of Translational Medical
Science, University of Naples Federico II, Naples, Italy
Background: Clostridium difficile infections (CDIs) caused by Clostridium difficile toxin A
(TcdA) lead to severe ulceration, inflammation and bleeding of the colon, and are difficult
to treat.
Aim: The study aimed to evaluate the effect of rifaximin on TcdA-induced apoptosis in
intestinal epithelial cells and investigate the role of PXR in its mechanism of action.
Methods: Caco-2 cells were incubated with TcdA and treated with rifaximin (0.1-10 µM)
with or without ketoconazole (10 µM). The transepithelial electrical resistance (TEER)
and viability of the treated cells was determined. Also, the expression of zona occludens-
1 (ZO-1), toll-like receptor 4 (TLR4), Bcl-2-associated X protein (Bax), transforming
growth factor-β-activated kinase-1 (TAK1), myeloid differentiation factor 88 (MyD88), and
nuclear factor-kappaB (NF-κB) was determined.
Results: Rifaximin treatment (0.1, 1.0, and 10 µM) caused a significant and
concentration-dependent increase in the TEER of Caco-2 cells (360, 480, and 680%
vs. TcdA treatment) 24 h after the treatment and improved their viability (61, 79, and
105%). Treatment also concentration-dependently decreased the expression of Bax
protein (−29, −65, and −77%) and increased the expression of ZO-1 (25, 54, and
87%) and occludin (71, 114, and 262%) versus TcdA treatment. The expression of TLR4
(−33, −50, and −75%), MyD88 (−29, −60, and −81%) and TAK1 (−37, −63, and
−79%) were also reduced with rifaximin versus TcdA treatment. Ketoconazole treatment
inhibited these effects.
Conclusion: Rifaximin improved TcdA-induced toxicity in Caco-2 cells by the PXR-
dependent TLR4/MyD88/NF-κB pathway mechanism, and may be useful in the
treatment of CDIs.
Keywords: Caco-2 cells, Clostridium difficile toxin A, pregnane X receptor, rifaximin, pseudomembranous colitis
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INTRODUCTION
Pseudomembranous colitis is a condition of the large intestine
characterized by inflammation and bleeding (Surawicz and
McFarland, 1999). It is mainly caused by the anaerobic Gram-
positive bacteria, Clostridium difficile. These spore producing
bacteria colonize the large intestine and produce toxins
[Clostridium difficile toxin A (TcdA) and Clostridium difficile
toxin B (TcdB)] which lead to severe diarrhea, colitis, shock and
death in severe cases (Rupnik et al., 2009; Leﬄer and Lamont,
2015). The cost of treatment and duration of hospitalization
is also significantly increased in affected individuals (Jodlowski
et al., 2006). Clostridium difficile infections (CDIs) are common
in hospital settings due to excessive use of antibiotics, which wash
out the normal gastrointestinal flora, making individuals more
vulnerable to bacterial attack (Rupnik et al., 2009). Currently
available treatment strategies for CDIs include the use of specific
antibiotics against Clostridium difficile, fecal transplant and
surgery (Waltz and Zuckerbraun, 2016). However, treatment of
severe and recurrent CDIs remains a challenge, with limited
treatment options available (Ebigbo and Messmann, 2013).
Rifaximin, a synthetic analog of rifamycin, is a broad spectrum
antibiotic effective against several Gram-positive as well as
Gram-negative aerobic and anaerobic bacteria (Scarpignato and
Pelosini, 2006). It is poorly absorbed on oral administration
and has no systemic adverse events (Scarpignato and Pelosini,
2005). Rifaximin is mainly used for the treatment of travelers’
diarrhea, hepatic encephalopathy, and irritable bowel syndrome
(Layer and Andresen, 2010; Sanchez-Delgado and Miquel, 2015;
Cash et al., 2016). Besides its antibiotic effect, rifaximin is a gut-
specific activator of human pregnane X receptor (PXR), which is
a nuclear receptor expressed in the small intestine that is involved
in maintaining the integrity of the intestinal epithelial barrier (Ma
et al., 2007; Cheng et al., 2010; Wan et al., 2015)
The aim of the present study was to evaluate the effect of
rifaximin on TcdA-induced apoptosis, using the Caco-2 cell line
as a model for the human intestinal barrier, and to investigate the
role of PXR in its mechanism of action.
MATERIALS AND METHODS
Caco-2 cells were purchased from European Collection of
Cell Cultures (ECACC, Public Health England Porton Down,
Salisbury, UK). Cell medium, chemicals and reagents used for
cell culture, and TcdA were purchased from Sigma–Aldrich (St.
Louis, MO, USA), unless otherwise stated. Instruments, reagents,
and materials used for western blot analysis were obtained from
Bio-Rad Laboratories (Milan, Italy). Rabbit anti-zona occludens-
1 (ZO-1), anti-occludin and anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibodies were procured from Cell
Signaling Technology (Danvers, MA, USA). Rabbit anti-toll-
like receptor 4 (TLR4), mouse anti-ZO-1, anti-Bcl-2-associated
X protein (Bax), mouse anti-MyD88, rabbit anti-transforming
growth factor-β-activated kinase-1 (pTAK1), and mouse anti-
TAK1 antibody were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA) and horseradish peroxidase (HRP) was
obtained from Dako (Milan, Italy). Fluorescein isothiocyanate-
conjugated anti-rabbit antibody and Texas red conjugated anti-
mouse antibody were purchased from Abcam (Cambridge, UK),
and custom oligonucleotides for electrophoretic mobility shift
assay (EMSA) analysis were synthesized by TIB Molbiol (Berlin,
Germany).
Cell Culture
Caco-2 cells were cultured in 6-well plates in Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% fetal bovine serum
(FBS), 1% penicillin–streptomycin, 2 mM L-glutamate, and 1%
non-essential amino acids. A total of 1 × 106 cells/well were
plated and incubated for 24 h. Upon reaching confluence, the cells
were washed three times with phosphate-buffered saline (PBS),
detached with trypsin/ethylene diamine tetraacetic acid (EDTA),
plated in a 10 cm diameter petri dish and allowed to adhere for
further 24 h.
The Caco-2 cells were randomly divided into six groups:
vehicle group, 30 ng/ml TcdA group, 30 ng/ml TcdA plus 0.1 µM
rifaximin, 30 ng/ml TcdA plus 1 µM rifaximin (Alfa Wasserman
S.p.A, Bologna, Italy), 30 ng/ml TcdA plus 10 µM rifaximin,
and 30 ng/ml TcdA plus 10 µM rifaximin plus 10 µM PXR
antagonist ketoconazole. Rifaximin concentrations were chosen
on the basis of previous studies (Terc et al., 2014). Depending
upon the experiments, Caco-2 cells were cultured in either 6-
well plates or 96-well plates. The cells were treated with different
concentrations of rifaximin (0.1–10 µM) and incubated at 37◦C
for 24 h, followed by TcdA exposure (30 ng/ml) for 24 h.
Transepithelial Electrical Resistance
Measurement
The transepithelial electrical resistance (TEER) of the epithelial
cell monolayer was determined using the EVOM volt-ohm
meter (World Precision Instruments Germany, Berlin, Germany)
according to the method described by Wells et al. (1998).
Briefly, cells plated between 14 and 21 days were used for
experimentation, and each epithelial cell layer with a TEER value
greater than 1000 /cm2, was considered to have tight adhesion.
TEER was calculated using the following formula: TEER
(/cm2) = (Total resistance − blank resistance) () × Area
(cm2).
Western Blot Analysis
Protein expression in the Caco-2 cells was evaluated using
western blot analysis. Following the treatments, the cells (1× 106
cells/well) were harvested, washed twice with ice-cold PBS and
centrifuged at 180 × g for 10 min at 4◦C. The pellet of
cells obtained after centrifugation was resuspended in 100 µl
ice-cold hypotonic lysis buffer [10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 1.5 mM MgCl2, 10 mM
KCl, 0.5 mM phenylmethylsulphonylfluoride, 1.5 µg/ml soybean
trypsin inhibitor, 7 µg/ml pepstatin A, 5 µg/ml leupeptin,
0.1 mM benzamidine and 0.5 mM dithiothreitol (DTT)]. The
suspension was rapidly passed through a syringe needle five to
six times to lyse the cells and then centrifuged for 15 min at
13,000 × g to obtain the cytoplasmic fraction. The proteins
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from the cytoplasmic fraction were mixed with a non-reducing
gel loading buffer [50 mM Tris(hydroxymethyl)aminomethane
(Tris), 10% sodium dodecyl sulfate (SDS), 10% glycerol, 2 mg
bromophenol/ml] at a 1:1 ratio, and boiled for 3 min followed
by centrifugation at 10,000 × g for 10 min. The protein
concentration was determined using the Bradford assay and
50 µg of each homogenate was used for electrophoresis using
polyacrylamide mini gels.
Proteins were transferred to nitrocellulose membranes that
were saturated by incubation with 10% non-fat dry milk in 1X
PBS overnight at 4◦C and then incubated with rabbit anti-ZO-
1, rabbit anti-occludin, rabbit anti-TLR4, rabbit anti-Bax, rabbit
anti-p-TAK1, mouse anti-TAK1, mouse anti-MyD88, or rabbit
anti-GAPDH antibodies, according to standard experimental
protocols. Membranes were then incubated with the specific
secondary antibodies conjugated to HRP. Immune complexes
were identified by enhanced chemiluminescence detection
reagents (Amersham Biosciences, Milan, Italy) and the blots
were analyzed by scanning densitometry (GS-700 Imaging
Densitometer; Bio-Rad, Segrate, Italy). Results were expressed
as optical density (OD; arbitrary units; mm2) and normalized
against the expression of the housekeeping protein GAPDH.
Immunofluorescence Staining Analysis
Caco-2 cells were harvested, washed with PBS, fixed in 4%
formaldehyde in PBS for 15 min and permeabilized with 0.3%
Triton-X100 in PBS for 1 h. Two percent bovine serum albumin
(BSA) was used to block the non-specific binding sites. The
cells were then incubated overnight with mouse anti-ZO-1
(1:100) and rabbit anti-occludin antibody (1:100), or rabbit
monoclonal anti-active caspase-3 (1:100; Abcam, Cambridge,
UK) and further incubated in the dark with the appropriate
secondary antibody (fluorescein isothiocyanate conjugated anti-
rabbit or Texas red conjugated anti-mouse). The cells were
analyzed using a microscope (Nikon Eclipse 80i), and images
were captured by a high-resolution digital camera (Nikon Digital
Sight DS-U1). Appropriate negative controls were done by
omitting primary or secondary antibodies.
Cytotoxicity Assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium
bromide (MTT) assay was used to determine cell proliferation
and survival in the Caco-2 cells (Mosmann, 1983). The cells
(5 × 104 cells/well) were plated in 96-well plates and allowed to
adhere for 3 h. DMEM was then replaced with fresh medium
and the cells were untreated or treated with 30 ng/ml TcdA alone
or together with increasing concentrations of rifaximin (0.1,
1.0, and 10 µM) dissolved in ultrapure and pyrogen-free sterile
vehicle, in the presence or absence of 10 µM ketoconazole. After
4 h, 25 µl MTT (5 mg/ml MTT in DMEM) was added to the
cells and the mixture was incubated for a further 3 h at 37◦C.
Subsequently, the cells were lysed and the dark blue crystals
were solubilized using a 100 µl solution containing 50% N,N-
dimethylformamide and 20% (w/v) SDS (pH 4.5). The OD of
each well was determined using a microplate spectrophotometer
equipped with a 620 nm filter (PerkinElmer, Inc; Waltham, MA,
USA).
Electrophoretic Mobility Shift Assay
Electrophoretic mobility shift assay was performed to detect
nuclear factor-kappaB (NF-κB) activation in Caco-2 cells after
TcdA with or without rifaximin treatment. Briefly, 10 mg of cell
extracts were incubated in a binding buffer (8 mM HEPES, pH
7.0, 10% glycerol, 20 mM KCl, 4 mM MgCl2, 1 mM sodium
pyrophosphate) containing 1.0 mg of poly(dI–dC) and γ-32P
end-labeled probe. The probe had a sequence as follows: A)
5′AAC TCC GGG AAT TTC CCT GGC CC3′ and B) 5′GGG
CCA GGG AAA TTC CCG GAG TT3′. Nuclear extracts were
incubated for 15 min with radiolabelled oligonucleotides (2.5–
5.0 × 104 cpm) in a 20 ml reaction buffer containing 2 mg
poly(dI-dC), 10 mM Tris–HCl (pH 7.5), 100 mM NaCl, 1 mM
EDTA, 1 mM DTT 1 mg/ml BSA, and 10% (v/v) glycerol.
Nuclear protein-oligonucleotide complexes were resolved by
electrophoresis on a 6% non-denaturing polyacrylamide gel in
Tris-Borate-EDTA buffer at 150 V for 2 h at 4◦C. The gel was
dried and autoradiographed with an intensifying screen at−80◦C
for 20 h. The relative bands were quantified by densitometric
scanning with Versadoc (Bio-Rad Laboratories) and a computer
program (Quantity One Software, Bio-Rad Laboratories).
DNA Fragmentation Assay
Following treatments Caco-2 cells were harvested, lysed with
400 µl sodium chloride EDTA buffer (75 mM NaCl and 25 mM
EDTA) containing 1% (w/v) SDS and 2 U/ml proteinase K, and
incubated for 2 h at 55◦C. Proteins were precipitated by adding
140 µl 5 M NaCl. After centrifugation, DNA in the supernatant
was precipitated by addition ethanol and centrifugation was
performed again (15 min; 11,000 × g). After washing with 70%
ethanol (v/v), the DNA was re-suspended in H2O, separated by
agarose gel electrophoresis and stained with ethidium bromide.
Statistical Analysis
Results were expressed as mean ± SEM of n = 5 experiments
in triplicate. Statistical analysis was performed using parametric
one way analysis of variance (ANOVA) and Bonferroni’s post hoc
test was used for multiple comparisons. P-values < 0.05 were
considered significant.
RESULTS
Transepithelial Electrical Resistance
The TEER values in the presence of rifaximin (0.1–10 µM) alone
or in the presence of ketoconazole (10 µM) were determined in
order to evaluate the barrier integrity of Caco-2 cells exposed
to 24 h of TcdA challenge. As seen in Figure 1A, a significant
time-dependent reduction in TEER was observed starting from
2 h after 30 ng/ml TcdA exposure when compared with the
vehicle group. The TEER values at 2, 3, 5, 7, 12, 18, and
24 h were −30,−37, −49, −57, −70, −82, and −91% versus
the vehicle group, respectively. Starting at 5 h following the
start of the toxin challenge, the effect of TcdA on TEER
decrease was significantly counteracted by rifaximin treatment in
a concentration-dependent manner. The TEER observed in the
0.1 µM rifaximin group at 5, 7, 12, 18, and 24 h was 19, 43, 56,
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FIGURE 1 | Effects of increasing concentrations of rifaximin (0.1, 1.0, and 10 µM) alone and rifaximin plus ketoconazole (10 µM) against TcdA
(30 ng/ml) in Caco-2 cells: (A) 24-h time course TEER changes (n = 4); (B) MTT cell viability absorbance at 24 h (n = 5); (C) Immunoreactive bands
corresponding to Bax, ZO-1, and occludin expression at 24 h following the TcdA challenge; (D) Relative densitometric analysis of immunoreactive
bands (arbitrary units normalized against the expression of the housekeeping GAPDH protein; n = 5), and (E) Immunofluorescent staining showing
the effects of TcdA challenge on ZO-1 and occludin co-expression at 24 h. Nuclei were also investigated using DAPI staining (Scale bar = 25 µm). Results
are expressed as mean ± SEM of experiments performed in triplicate. ∗∗∗p < 0.001 and ∗∗p < 0.01 vs. vehicle group; ◦◦◦p < 0.001, ◦◦p < 0.01 and ◦p < 0.05 vs.
TcdA group.
177, and 360%, and in the 1.0 µM rifaximin group was 36, 69,
103, 233, and 480%, when compared with the TcdA group. When
rifaximin 10 mM was used, TEER reduction was seen starting at
2 h following TcdA stimulus and continued for all the time point
intervals (24, 28, 57, 93, 150, 350, and 680% vs. the TcdA group
at 2, 3, 5, 7, 12, 18, and 24 h; Figure 1A). The effect of rifaximin
on the TEER was abolished by the treatment with ketoconazole
(Figure 1A).
Cell Viability and Cytotoxicity
As seen in Figure 1B, a significant decrease in Caco-2 cell viability
(−54%) was observed at 24 h following the TcdA challenge,
when compared with the vehicle group (assumed to be 100%
viable cells). Under the same experimental conditions, rifaximin
caused a significant and concentration-dependent inhibition of
cytotoxicity induced by TcdA, resulting in an increased viability
of the cultured cells (61, 79, and 105% with 0.1, 1.0, and 10 µM
rifaximin, respectively, vs. TcdA group). The effect of rifaximin
was almost totally inhibited by ketoconazole (Figure 1B).
Western Blot and Immunofluorescence
Staining
The TcdA challenge caused a significant increase in pro-
apoptotic Bax protein expression in Caco-2 cell homogenates
(955%; p < 0.001 vs. vehicle), as seen in Figures 1C,D.
Treatment with rifaximin resulted in a concentration-dependent
decrease in Bax protein expression under the same experimental
conditions (−29, −65, and −77% with 0.1, 1.0, and 10 µM
rifaximin, respectively, vs. TcdA group). Here again, this anti-
apoptotic effect of rifaximin was reverted by ketoconazole
(Figures 1C,D). To further confirm the ability of rifaximin to
significantly affect the TcdA-induced apoptosis also the DNA
fragmentation and the expression of caspase-3 were significantly
and, in a similar PXR-manner, reduced (Supplementary
Figure S1).
Also, there was a significant decrease in the expression
of ZO-1 (−75%) and occludin (−50%) 24 h after the TcdA
exposure (Figures 1C,D), versus their respective vehicle
groups. Along with its protective effect on cell viability,
rifaximin concentration-dependently increased ZO-1 (0.1,
1.0, and 10 µM rifaximin: 25, 54, and 87%, respectively, vs.
TcdA group) and occludin (71, 114, and 262%, respectively,
vs. TcdA group) expression. Immunofluorescence analysis
(Figures 1C–E) showed that rifaximin, at a dose of 10 µM,
resulted in an impressive preservation of epithelial barrier
architecture, counteracting TcdA-induced decrease in ZO-1
and occludin co-expression in cultured cells (Figure 1E).
Once again, ketoconazole caused complete loss of the
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FIGURE 2 | Rifaximin (0.1, 1.0, and 10 µM) down-regulates the TLR4/MyD88/NF-κB pathway by a PXR-dependent mechanism. (A) Immunoblot showing
the TLR4, MyD88, and phosphorylated/unphosphorylated TAK1 protein bands, and (B) Relative densitometric analysis of immunoreactive bands (arbitrary units
normalized against the expression of the housekeeping GAPDH protein) showing the effects of rifaximin, given alone or in the presence of ketoconazole (10 µM), on
the expression of TLR4, MyD88, and pTAK1 in Caco-2 cell line. (C) EMSA analysis showing concentration-dependent inhibition of NF-κB activation by rifaximin, and
(D) Relative densitometric analysis of NF-κB bands. Results are expressed as mean ± SEM of n = 5 experiments performed in triplicate. ∗∗∗p < 0.001 vs. vehicle
group; ◦◦◦p < 0.001, ◦◦p < 0.01 and ◦p < 0.05 vs. TcdA group.
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rifaximin-mediated rescue of ZO-1 and occludin proteins
(Figures 1C,D).
TLR4/MyD88/NF-κB Expression
There was a significant increase in the expression of TLR4
(1411%) and myeloid differentiation factor 88 (MyD88; 1250%),
and phosphorylation of TAK1 (2800%) in the Caco-2 cells
24 h after the TcdA challenge, when compared with the vehicle
group (Figures 2A,B). The EMSA analysis showed significant
up-regulation of NF-κB activity by TcdA versus the vehicle
group (348%; Figures 2A,B). Rifaximin at 0.1, 1.0, and 10 µM
inhibited TLR4 expression (−33, −50, and −75%) and reduced
MyD88 (−29, −60, and −81%) and TAK1 expression (−37,
−63, and −79%) in a concentration-dependent manner, when
compared with the TcdA group (Figures 2A,B). Also, rifaximin
caused a significant and concentration-dependent decrease in
the expression of NF-κB (−38, −50, and −63% at 0.1, 1.0, and
10 µM, respectively, vs. TcdA group; Figures 2C,D). These effects
of rifaximin were inhibited by ketoconazole (Figure 2).
DISCUSSION
In the present study, treatment with rifaximin significantly
increased the TEER in Caco-2 cells in a time-dependent manner
when compared with TcdA treatment. Treatment also reduced
the cytotoxicity of the TcdA challenge and improved cell viability.
Further, rifaximin caused a concentration-dependent decrease
in the expression of Bax, caspase-3, and an increase in ZO-1
and occludin expression, and inhibited the expression of TLR4,
MyD88, TAK1, and NF-κB in the Caco-2 cells. These effects of
rifaximin were inhibited by the PXR antagonist, ketoconazole.
Transepithelial electrical resistance measurement is used as
an index of monolayer confluence and integrity in cell culture
experiments (Huynh-Delerme et al., 2005). TEER has also been
used to measure the paracellular permeability of cell monolayers
(Madara et al., 1988). In the present study, TcdA challenge caused
a time-dependent marked loss of electrical resistance and barrier
integrity of the Caco-2 cells, as seen by the reduction in the TEER
after the challenge. Rifaximin treatment improved the TEER
values and cell viability in a concentration-dependent manner,
demonstrating its efficacy in the prevention of TcdA-induced
apoptosis and maintaining barrier integrity. That the effects of
rifaximin were inhibited by the PXR antagonist ketoconazole,
indicates the mechanism of action of rifaximin involves PXR.
Treatment with rifaximin also caused a decrease in the
expression of Bax, and an increase in the expression of ZO-1
and occludin in the Caco-2 cells, in a concentration-dependent
manner, and preserved the epithelial barrier architecture in the
cultured cells. ZO-1 is a tight junction protein that interacts
with the transmembrane protein occludin to maintain the cell
barrier integrity (Fanning et al., 1998). while Bax is a protein
involved in the promotion of apoptosis (Pawlowski and Kraft,
2000; Westphal et al., 2011) Thus, a decrease in Bax expression
should decrease the likelihood of apoptosis, and an increase
in ZO-1 and occludin expression should ensure maintenance
of barrier integrity, which is what was seen in the present
study, with rifaximin effectively maintaining the integrity of
the Caco-2 epithelial cell barrier and down-regulating the
apoptotic signaling pathway. Again, these effects of rifaximin
were completely reversed by ketoconazole, suggesting a PXR-
dependent mechanism of action.
Rifaximin treatment also down-regulated the TLR4/MyD88/
NF-κB pathway induced by TcdA, through a PXR-dependent
mechanism. TLR4 is a transmembrane receptor that is
overexpressed in tumor cells (Rakoff-Nahoum and Medzhitov,
2009). TLR4 and its adaptor proteins MyD88 and TAK1 are
involved in the activation of the NF-κB pathway causing
the release of inflammatory mediators (Akira and Hoshino,
2003; O’Neill et al., 2003; Sato et al., 2005; Kawai and Akira,
2007) In the present study, treatment with rifaximin caused a
significant reduction in the expression of TLR4, MyD88, TAK1,
and NF-κB after the TcdA challenge, indicating its usefulness
in the prevention of TcdA-induced apoptosis by acting on
the inflammatory environment. Once again, ketoconazole
co-incubation showed complete loss of rifaximin-mediated
suppression of these proteins, indicating a role for PXR in these
changes.
Pregnane X receptor is a receptor belonging to the nuclear
receptor subfamily that are present in the liver and intestine,
which are involved in the clearance of xenobiotics from cells
(Mani et al., 2013; Smutny et al., 2013). Activation of PXR
promotes the expression of several enzymes and transporters
that assist in detoxification and removal of xenobiotics, and
help in maintaining the integrity of the intestinal barrier (Zhang
et al., 2008; Mencarelli et al., 2010). PXR activation also leads
to inhibition of the NF-κB pathway and reduces the expression
of inflammatory mediators (Cheng et al., 2010; Dou et al.,
2012; Zhang et al., 2015) In the present study, reversal of
the effects of rifaximin by the PXR antagonist ketoconazole
confirm the role of PXR in its mechanism of action. Thus, it
appears that rifaximin activates PXR in Caco-2 cells leading to a
reduction in TcdA-induced inflammation by down-regulation of
the TLR4/MyD88/NF-κB pathway, and improvement of the cell
layer integrity.
Rifaximin is a poorly absorbed antibiotic with a favorable
safety profile (Scarpignato and Pelosini, 2005). Due to its poor
absorption, most of the drug is available in the intestine to locally
exert its effects on TcdA-induced apoptosis in the colon. Thus, it
may be a promising molecule in the treatment of CDIs.
CONCLUSION
Rifaximin effectively inhibited TcdA-induced apoptosis in a
cellular model of the intestinal barrier by a PXR-dependent
TLR4/MyD88/NF-κB pathway mechanism. Further studies in
clinical settings are required to confirm its efficacy in the
treatment of CDIs.
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FIGURE S1 | (A) Agarose gel electrophoresis of cultured Caco-2 cell DNA in the
presence of TcdA (30 ng/ml) alone or in the presence of increasing concentration
of rifaximin (0.1–10 µM) for 24 h. Rifaximin (10 µM) was tested either alone, or in
the presence of the PXR antagonist ketoconazole (10 µM). Ketoconazole alone
was unable to exert any significant effect on DNA damage. The results are
representative of n = 3 independent experiments. (B) Western blot analysis
showing immunoreactive bands referred to the pro-apoptotic active Caspase-3
protein. TcdA (30 ng/ml) induced a significant increase of Caspase-3 expression,
that was significantly and concentration-dependently reduced by Rifaximin, whose
effect was significantly inhibited by ketoconazole (10 µM). Ketoconazole alone had
no pro-apoptotic effect. (C) Relative quantification of immunoreactive bands of
active caspase-3 protein (arbitrary units). Results are expressed as the
mean ± SEM of n = 4 experiments performed in triplicate. ∗∗∗P < 0.001 vs.
vehicle group; ◦◦◦P < 0.001, ◦◦P < 0.01 vs. TcdA group.
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